Myrobalan Therapeutics key facts
- Operator of a therapeutic biotechnology company intended for developing oral neurorestorative therapies aimed at reversing key pathologies underlying brain dysfunctions and central nervous system…
- It has raised $43.0M; the latest was Grant ($850K) in Mar 2025.
- Notable investors include Johnson & Johnson Innovation - JLABS, Co-Win Ventures, Proxima Ventures (China), 3E Bioventures Capital, AB Magnitude Ventures Group — 9 tracked in total.
- Status: Privately Held (backing).
- ·Watch Myrobalan Therapeutics: the Monday email on marks, rounds and moves
Myrobalan Therapeutics funding rounds
No funding rounds for Myrobalan Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Myrobalan Therapeutics investors
9 investors are on record for Myrobalan Therapeutics, including Johnson & Johnson Innovation - JLABS, Co-Win Ventures, Proxima Ventures (China) and 3E Bioventures Capital.
About Myrobalan Therapeutics
Operator of a therapeutic biotechnology company intended for developing oral neurorestorative therapies aimed at reversing key pathologies underlying brain dysfunctions and central nervous system (CNS) conditions. The company offers neurological processes such as demyelination and neuroinflammation and innovative drug discovery tools to create selective and brain-penetrant therapeutic candidates that are positioned for addressing unmet medical needs in CNS diseases, enabling healthcare professionals to provide therapeutic opportunities for a large patient population with unmet medical needs.
- Sector
- Healthcare
- HQ
- Medford, MA, United States
- Founded
- 2021
- Employees
- 19
- Website
- myrotx.com/
- Ownership
- Privately Held (backing)
Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.
Myrobalan Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.